Lundbeck Nasdaq Copenhagen

LUN

DK0061804697

H Lundbeck A/S is a Denmark-based company active in the pharmaceuticals industry. It is engaged in the research, development, manufacture and marketing of pharmaceuticals for the treatment of brain disorders, such as Alzheimerâs disease, Bipolar disorder, depression, epilepsy, Huntingtonâs disease, Parkinsonâs disease and schizophrenia. Its product portfolio includes: Cipralex for the treatment of depression and anxiety disorders, Ebixa for the treatment of Alzheimerâs disease, Azilect for the treatment of Parkinsonâs disease, Xenazine for the treatment of Huntingtonâs disease and Sabril for the treatment of epilepsy, among others. The Company operates through a number of subsidiaries, such as Lundbeck SAS, Lundbeck GmbH, SIA Lundbeck Latvia and Lundbeck LLC.

Sector

Pharmaceuticals

Calendar

2024-08-20 - Q2 2024 Earnings Release

More about the company

Income Statement Evolution

More financial data

Analysis / Opinion

H LUNDBECK : Q1 beat adds momentum to the recent share price rally

May 15, 2024 at 12:20 pm

More Strategies

Ratings for Lundbeck

Trading Rating

Investor Rating

ESG Refinitiv

B-

More Ratings

Analysts' Consensus

Sell

Buy

Mean consensus

OUTPERFORM

Number of Analysts

Last Close Price

37.32 DKK

Average target price

39.96 DKK

Spread / Average Target

+7.07%

Consensus

EPS Revisions

Estimates Revisions

Quarterly earnings - Rate of surprise

Company calendar

Sector Pharmaceuticals Wholesale

	1st Jan change	Capi.
LUNDBECK	-6.20%	5.21B
MCKESSON CORPORATION	+20.53%	72.45B
CARDINAL HEALTH, INC.	-4.71%	23.46B
SINOPHARM GROUP CO. LTD.	+4.89%	8.59B
SHANGHAI PHARMACEUTICALS HOLDING CO., LTD	+7.11%	8.35B
HUADONG MEDICINE CO., LTD	-23.73%	7.88B
EBOS GROUP LIMITED	-0.59%	4.11B
JOINTOWN PHARMACEUTICAL GROUP CO., LTD	+7.85%	4.09B
CHINA NATIONAL MEDICINES CORPORATION LTD.	+20.65%	3.6B
MEDIPAL HOLDINGS CORPORATION	-1.82%	2.98B

Pharmaceuticals Wholesale

Market Closed - Nasdaq Copenhagen Other stock markets 10:59:40 2024-05-23 EDT			5-day change	1st Jan Change
32.4 ^DKK	-0.15%		-0.15%	-6.20%

05-15	H LUNDBECK : Q1 beat adds momentum to the recent share price rally
05-15	Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024

H LUNDBECK : Q1 beat adds momentum to the recent share price rally	05-15
Transcript : H. Lundbeck A/S, Q1 2024 Earnings Call, May 15, 2024	05-15
H. Lundbeck A/S Reports Earnings Results for the First Quarter Ended March 31, 2024	05-15	CI
H. Lundbeck A/S Provides Earnings Guidance for the Year 2024	05-15	CI
H LUNDBECK : Lundbeck is well-poised to sail through the transition period	05-13
H. Lundbeck A/S Appoints Announces the Appointment of Maria Alfaiate as EVP, Commercial and Corporate Strategy, Effective 1 August 2024	05-13	CI
H. Lundbeck, Otsuka Pharmaceutical Seek US FDA Nod for PTSD Combination Therapy	04-09	MT
Lundbeck and Otsuka submit sNDA for FDA review of brexpiprazole and sertraline combination as potential treatment for PTSD	04-09	CI
EU Commission Green-lights Lundbeck, Otsuka's Abilify Maintena as Maintenance Treatment of Schizophrenia	03-27	MT
Otsuka Pharmaceutical Europe Ltd. and H. Lundbeck A/S Announces Approval in the EU for the Maintenance Treatment of Schizophrenia	03-27	CI
H. Lundbeck A/S Announces Management Appointments	03-20	CI
H. Lundbeck A/S Approves Dividend for the Accounting Year 2023	03-20	CI
Transcript : H. Lundbeck A/S - Shareholder/Analyst Call	03-20
H. Lundbeck Plans Clinical Development of Migraine Prevention Drug	03-15	MT
H. Lundbeck A/S Announces Potential First-In-Class Therapy for Migraine Prevention Enters Advanced Clinical Stage	03-15	CI
H. Lundbeck A/S Proposes Dividend for the Accounting Year 2023	02-23	CI
H. Lundbeck A/S Announces Changes to Executive Management	02-23	CI
Nordic Shares Dropped Tuesday; Lundin Gold Posted Biggest Loss	02-13	DJ
Transcript : H. Lundbeck A/S, 2023 Earnings Call, Feb 07, 2024	02-07
Transcript : H. Lundbeck A/S - Special Call	01-31
Transcript : H. Lundbeck A/S - Special Call	11-30